- The U.S. Department of Health and Human Services (HHS) exercised an option to buy an additional 10K doses of BioCryst Pharmaceuticals' ( NASDAQ: BCRX ) antiviral influenza therapy Rapivab for ~$7M.
- Rapivab (peramivir injection) purchase by the HHS Administration for Strategic Preparedness and Response is aimed to prepare for a potential pandemic influenza event.
- The order is the final of five purchase options of a $34.7M contract by the Centers for Disease Control and Prevention in 2018 to get up to 50k doses of Rapivab over five years.
- After this new order is filled BioCryst would have delivered all 50K doses to the U.S. government.
- BCRX +1.82% to $15.08 premarket Aug. 25
For further details see:
BioCryst to supply 10K doses of influenza drug Rapivab to US for ~$7M